DrugS

The Department of Health and Human Services released the administration’s Comprehensive Plan for Addressing High Drug Prices in response to President Biden’s executive order that identified a lack of industry competition as a key driver of high drug prices. Read More.

G1 Therapeutics, Inc. secures permanent J Code for COSELA™ (trilaciclib). The code, J1448, is effective on October 1, 2021. Visit COSELA.com for more information.

Oncopeptides announces J-code J9247 for Pepaxto® (melphalan flufenamide) injection, 1mg. This J-code will be effective on October 1, 2021.

Novartis announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. These data will be presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 on September 19 (#LBA17).  Read More.

Effective July 1, 2020, the following code J9358 can be used to identify ENHERTU® (fam-trastuzumab deruxtecan-nxki) when billing across settings of care as noted in the CMS HCPCS Application Summaries and Coding Decisions.

Astellas announces the assignment of a product-specific, permanent J-code for PADCEV. The Centers for Medicare & Medicaid Services (CMS) released the July 2020 Quarterly Healthcare Common Procedural Coding System (HCPCS) File, which includes the designation of J9177 for PADCEV with the effective date of July 1, 2020.